Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanidatamab zovodotin - Zymeworks

Drug Profile

Zanidatamab zovodotin - Zymeworks

Alternative Names: anti-HER2 x HER2 ADC - Zymeworks; ZW-49

Latest Information Update: 15 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymeworks
  • Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I HER2 positive breast cancer; Oesophageal cancer; Solid tumours
  • Preclinical Gastric cancer

Most Recent Events

  • 04 Jan 2024 Zymeworks plans a phase II trial for zanidatamab zovodotin in non-small cell lung cancer in 2024
  • 11 Oct 2023 Efficacy, adverse event, and pharmacokinetics data from a phase I trial in Oesophageal-cancer, Solid-tumours , and HER2-positive-breast-cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
  • 28 Apr 2023 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top